

Noel Chan Mbbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2151108/publications.pdf>

Version: 2024-02-01

70
papers

1,510
citations

304368

22
h-index

329751

37
g-index

70
all docs

70
docs citations

70
times ranked

2012
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct oral anticoagulants: evidence and unresolved issues. <i>Lancet</i> , The, 2020, 396, 1767-1776.	6.3	100
2	Evolving Treatments for Arterial and Venous Thrombosis. <i>Circulation Research</i> , 2016, 118, 1409-1424.	2.0	96
3	COVID-19 coagulopathy, thrombosis, and bleeding. <i>Blood</i> , 2020, 136, 381-383.	0.6	96
4	Prevention of Venous Thromboembolism in 2020 and Beyond. <i>Journal of Clinical Medicine</i> , 2020, 9, 2467.	1.0	82
5	Laboratory measurement of the direct oral anticoagulants. <i>British Journal of Haematology</i> , 2016, 172, 315-336.	1.2	79
6	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. <i>Journal of the American Heart Association</i> , 2015, 4, e002322.	1.6	78
7	Antithrombotic Agents. <i>Circulation Research</i> , 2019, 124, 426-436.	2.0	76
8	Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. <i>Vascular Health and Risk Management</i> , 2015, 11, 343.	1.0	68
9	Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 684-688.	1.0	66
10	Real-world variability in dabigatran levels in patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 353-359.	1.9	62
11	Novel antithrombotic strategies for treatment of venous thromboembolism. <i>Blood</i> , 2020, 135, 351-359.	0.6	51
12	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. <i>Thrombosis and Haemostasis</i> , 2014, 111, 798-807.	1.8	48
13	Peripheral Oxygen Saturation in Older Persons Wearing Nonmedical Face Masks in Community Settings. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2323.	3.8	45
14	Advances in Antithrombotic Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 7-12.	1.1	42
15	Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. <i>American Heart Journal</i> , 2018, 199, 59-67.	1.2	36
16	Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. <i>Future Cardiology</i> , 2014, 10, 43-52.	0.5	33
17	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 231-239.	1.0	32
18	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , 2017, 01, e139-e145.	0.7	31

#	ARTICLE	IF	CITATIONS
19	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , 2014, 124, 689-699.	0.6	28
20	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section Vê”Special Situations. <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	1.8	28
21	Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1049-1057.	1.8	26
22	Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 668-674.	1.8	24
23	Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?â€”A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1323-1329.	1.8	22
24	Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007019.	1.4	20
25	Anticoagulation for Mechanical Heart Valves. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 743-745.	1.1	17
26	Fifty years of research on antithrombotic therapy: Achievements and disappointments. <i>European Journal of Internal Medicine</i> , 2019, 70, 1-7.	1.0	17
27	Timing the First Postoperative Dose of Anticoagulants. <i>Chest</i> , 2015, 148, 587-595.	0.4	15
28	How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. <i>Blood</i> , 2019, 133, 2269-2278.	0.6	15
29	No apparent association between mRNA COVID-19 vaccination and venous thromboembolism. <i>Blood Reviews</i> , 2022, 56, 100970.	2.8	12
30	Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. <i>Thrombosis and Haemostasis</i> , 2019, 119, 689-694.	1.8	11
31	Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?. <i>European Heart Journal</i> , 2021, 42, 3143-3145.	1.0	11
32	Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. <i>Thrombosis and Haemostasis</i> , 2014, 111, 10-13.	1.8	10
33	Incidence and risk factors for acute kidney injury in patients with excessive anticoagulation on warfarin: a retrospective study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 557-561.	1.0	10
34	In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1895-1901.	1.8	8
35	MAA868 locks factor XIa in a zymogen-like state. <i>Blood</i> , 2019, 133, 1393-1394.	0.6	8
36	A National Canadian Survey of Antithrombotic Therapy After Urgent and Emergent Limb Revascularization. <i>Canadian Journal of Cardiology</i> , 2021, 37, 504-507.	0.8	8

#	ARTICLE	IF	CITATIONS
37	AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 533-535.	1.1	7
38	Rivaroxaban for prevention and treatment of venous thromboembolism. <i>Future Cardiology</i> , 2019, 15, 63-77.	0.5	7
39	Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease. <i>Canadian Journal of Cardiology</i> , 2022, 38, 588-600.	0.8	7
40	Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12650.	1.0	7
41	Real-world variability in dabigatran levels in patients with atrial fibrillation: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1168-1169.	1.9	6
42	Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2906-2907.	1.2	6
43	Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 187-195.	1.5	5
44	Recent advances in understanding, diagnosing and treating venous thrombosis. <i>F1000Research</i> , 2020, 9, 1206.	0.8	5
45	Bleeding in patients with atrial fibrillation treated with combined antiplatelet and anticoagulant therapy: time to turn the corner. <i>Annals of Translational Medicine</i> , 2019, 7, S198-S198.	0.7	5
46	Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making. <i>Canadian Journal of Cardiology</i> , 2022, 38, 654-661.	0.8	5
47	Thromboembolism in Older Adults. <i>Frontiers in Medicine</i> , 2020, 7, 470016.	1.2	4
48	Medical Therapy Following Urgent/Emergent Revascularization in Peripheral Artery Disease Patients (Canadian Acute Limb Ischemia Registry [CANALISE I]). <i>CJC Open</i> , 2021, 3, 1325-1332.	0.7	4
49	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study. <i>TH Open</i> , 2022, 06, e10-e17.	0.7	4
50	The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. <i>CJC Open</i> , 2022, 4, 568-576.	0.7	4
51	Platelet function testing: does a randomized controlled trial settle the debate?. <i>Journal of NeuroInterventional Surgery</i> , 2016, 8, 768-769.	2.0	3
52	Are Ticks the Answer to Medical Device-Associated Clotting?. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2190-2192.	1.2	3
53	Net benefit of ticagrelor in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2016, 12, 10-11.	4.1	2
54	Response by Chan and Weitz to Letter Regarding Article, "Antithrombotic Agents: New Directions in Antithrombotic Therapy". <i>Circulation Research</i> , 2019, 124, e119.	2.0	2

#	ARTICLE	IF	CITATIONS
55	Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?. TH Open, 2021, 05, e84-e88.	0.7	2
56	Prevention and Management of Urgent/Emergent Limb Ischemia. Current Cardiology Reports, 2021, 23, 41.	1.3	2
57	Management of a Left Atrial Appendage Thrombus Due to Atrial Fibrillation Complicating Quinacrine Platelet Disorder. Canadian Journal of Cardiology, 2022, 38, 1464-1466.	0.8	2
58	Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants. Expert Review of Cardiovascular Therapy, 2015, 13, 1213-1223.	0.6	1
59	Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done?. Thrombosis and Haemostasis, 2017, 117, 2213-2214.	1.8	1
60	Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. Blood Advances, 2018, 2, 1806-1806.	2.5	1
61	Refining Risk Prediction for Recurrent Venous Thromboembolism: Can We Do Better?. Thrombosis and Haemostasis, 2020, 120, 725-727.	1.8	1
62	The conundrum of resuming anticoagulant therapy after intracerebral bleeding: In whom, when, and how?. Vascular Medicine, 2020, 25, 60-62.	0.8	1
63	Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 218-232.	0.8	1
64	Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1091-1102.	1.5	1
65	In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding. Annals of Internal Medicine, 2017, 167, JC17.	2.0	0
66	The value of novel oral anticoagulants in rural Australia. Medical Journal of Australia, 2018, 208, 15-16.	0.8	0
67	Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications. , 2019, , 1067-1077.		0
68	Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease. Future Cardiology, 2020, 16, 597-611.	0.5	0
69	Optimal Prescription of the Lower Dose of Apixaban. Journal of the American College of Cardiology, 2020, 75, 1156-1158.	1.2	0
70	In pregnant women with suspected VTE and low/intermediate or unlikely pretest probability, D-dimer rules out VTE at 3 mo. Annals of Internal Medicine, 2021, 174, JC130.	2.0	0